Trial Outcomes & Findings for Comparison of Rimegepant and Placebo for Pain in IBS (NCT NCT06221111)

NCT ID: NCT06221111

Last Updated: 2026-05-22

Results Overview

The change in daily abdominal pain scores will be assessed using the 100-mm Visual Analogue Scale (VAS). The VAS line will be 100 mm long with no intermediate delineations. Each end will be marked with "no pain" on the left, and "worst possible pain" on the right. Participants will identify their pain level by indicating a point on the line between each end. That point will be measured from the "No pain" end, and the number of millimeters will be reported as the pain score. Total scores range from 0 to 100 with higher scores indicating worse pain.

Recruitment status

COMPLETED

Study phase

PHASE2

Target enrollment

39 participants

Primary outcome timeframe

Baseline; Day 28

Results posted on

2026-05-22

Participant Flow

39 participants were enrolled in the study, 10 of which were excluded prior to randomization due to screening failing and 5 of which were excluded prior to randomization due to withdrawing.

Participant milestones

Participant milestones
Measure
Rimegepant
* Rimegepant 75mg oral dissolving tablet (ODT) * Formulation and Dosing as FDA-approved for Migraine Prevention: 75 mg Every Other Day (EOD) for 4 weeks/30 days Rimegepant 75 MG \[Nurtec\]: placebo controlled trial
Placebo
Placebo ODT appearing identical to the experimental formulation and administered every other day for 4 weeks/30 days Rimegepant 75 MG \[Nurtec\]: placebo controlled trial
Overall Study
STARTED
12
12
Overall Study
COMPLETED
12
12
Overall Study
NOT COMPLETED
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Comparison of Rimegepant and Placebo for Pain in IBS

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Rimegepant
n=12 Participants
* Rimegepant 75mg oral dissolving tablet (ODT) * Formulation and Dosing as FDA-approved for Migraine Prevention: 75 mg Every Other Day (EOD) for 4 weeks/30 days Rimegepant 75 MG \[Nurtec\]: placebo controlled trial
Placebo
n=12 Participants
Placebo ODT appearing identical to the experimental formulation and administered every other day for 4 weeks/30 days Rimegepant 75 MG \[Nurtec\]: placebo controlled trial
Total
n=24 Participants
Total of all reporting groups
Age, Continuous
38 years
n=2 Participants
38 years
n=4 Participants
38.0 years
n=6 Participants
Sex: Female, Male
Female
10 Participants
n=2 Participants
7 Participants
n=4 Participants
17 Participants
n=6 Participants
Sex: Female, Male
Male
2 Participants
n=2 Participants
5 Participants
n=4 Participants
7 Participants
n=6 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants
n=2 Participants
0 Participants
n=4 Participants
0 Participants
n=6 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
12 Participants
n=2 Participants
12 Participants
n=4 Participants
24 Participants
n=6 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
n=2 Participants
0 Participants
n=4 Participants
0 Participants
n=6 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=2 Participants
0 Participants
n=4 Participants
0 Participants
n=6 Participants
Race (NIH/OMB)
Asian
0 Participants
n=2 Participants
0 Participants
n=4 Participants
0 Participants
n=6 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=2 Participants
0 Participants
n=4 Participants
0 Participants
n=6 Participants
Race (NIH/OMB)
Black or African American
0 Participants
n=2 Participants
0 Participants
n=4 Participants
0 Participants
n=6 Participants
Race (NIH/OMB)
White
12 Participants
n=2 Participants
12 Participants
n=4 Participants
24 Participants
n=6 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=2 Participants
0 Participants
n=4 Participants
0 Participants
n=6 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=2 Participants
0 Participants
n=4 Participants
0 Participants
n=6 Participants
Region of Enrollment
United States
12 participants
n=2 Participants
12 participants
n=4 Participants
24 participants
n=6 Participants

PRIMARY outcome

Timeframe: Baseline; Day 28

The change in daily abdominal pain scores will be assessed using the 100-mm Visual Analogue Scale (VAS). The VAS line will be 100 mm long with no intermediate delineations. Each end will be marked with "no pain" on the left, and "worst possible pain" on the right. Participants will identify their pain level by indicating a point on the line between each end. That point will be measured from the "No pain" end, and the number of millimeters will be reported as the pain score. Total scores range from 0 to 100 with higher scores indicating worse pain.

Outcome measures

Outcome measures
Measure
Rimegepant
n=12 Participants
* Rimegepant 75mg oral dissolving tablet (ODT) * Formulation and Dosing as FDA-approved for Migraine Prevention: 75 mg Every Other Day (EOD) for 4 weeks/30 days Rimegepant 75 MG \[Nurtec\]: placebo controlled trial
Placebo
n=12 Participants
Placebo ODT appearing identical to the experimental formulation and administered every other day for 4 weeks/30 days Rimegepant 75 MG \[Nurtec\]: placebo controlled trial
Change in Abdominal Pain Scores
-12 score on a scale
Interval -16.9 to -6.4
-22.6 score on a scale
Interval -30.3 to -8.1

SECONDARY outcome

Timeframe: Baseline; Day 28

The change in bowel movement frequency measured by the number of bowel movements a participant reported having each day from baseline through day 28.

Outcome measures

Outcome measures
Measure
Rimegepant
n=12 Participants
* Rimegepant 75mg oral dissolving tablet (ODT) * Formulation and Dosing as FDA-approved for Migraine Prevention: 75 mg Every Other Day (EOD) for 4 weeks/30 days Rimegepant 75 MG \[Nurtec\]: placebo controlled trial
Placebo
n=12 Participants
Placebo ODT appearing identical to the experimental formulation and administered every other day for 4 weeks/30 days Rimegepant 75 MG \[Nurtec\]: placebo controlled trial
Change in Bowel Movement Frequency
-0.2 bowel movements per day
Interval -0.8 to 0.0
-0.9 bowel movements per day
Interval -1.0 to -0.4

SECONDARY outcome

Timeframe: Baseline; Day 28

The change in rectal compliance threshold defined as the change in pressure at half maximum volume (Pr 1/2) measured using a rectal barostat device. The rectal barostat device is a rectal catheter with a polyethylene bag attached (length 22 cm; capacity 600 ml) that is inserted into the rectum and connected to a barostat. The bag is unfolded by inflation with 75 ml of air, followed by complete deflation. After a 10 minute recovery period, the pressure is increased from 0 mmHg in steps of 4 mmHg for 15 seconds per step until 20 mmHg is reached. The observed volume/maximum observed volume will be used to obtain a pressure corresponding to half the maximum observed volume. A calculation of the pressures corresponding to the volumes just above and just below the half maximum volume will provided the specific pressure (Pr 1/2) corresponding to one half of the maximum observed volume.

Outcome measures

Outcome measures
Measure
Rimegepant
n=12 Participants
* Rimegepant 75mg oral dissolving tablet (ODT) * Formulation and Dosing as FDA-approved for Migraine Prevention: 75 mg Every Other Day (EOD) for 4 weeks/30 days Rimegepant 75 MG \[Nurtec\]: placebo controlled trial
Placebo
n=12 Participants
Placebo ODT appearing identical to the experimental formulation and administered every other day for 4 weeks/30 days Rimegepant 75 MG \[Nurtec\]: placebo controlled trial
Change in Rectal Compliance
2.1 mmHg
Interval -1.3 to 7.0
-0.1 mmHg
Interval -4.2 to 2.2

SECONDARY outcome

Timeframe: Baseline; Day 28

The change in rectal sensation pain threshold in response to the pressure in the balloon escalating from 0 mmHg to 44 mmHg at 4 mmHg stepwise increases measured using the 100-mm Visual analog scale (VAS). The scale ranges from (unnoticeable) to (unbearable). The VAS line will be 100 mm long with no intermediate delineations. Each end will be marked with "unnoticeable" on the left, and "unbearable" on the right. Participants will identify their level of pain by indicating a point on the line between each end. That point will be measured from the "unnoticeable" end, and the number of millimeters will be reported as the pain score. Total scores range from 0 to 100 with higher scores indicating worse pain.

Outcome measures

Outcome measures
Measure
Rimegepant
n=12 Participants
* Rimegepant 75mg oral dissolving tablet (ODT) * Formulation and Dosing as FDA-approved for Migraine Prevention: 75 mg Every Other Day (EOD) for 4 weeks/30 days Rimegepant 75 MG \[Nurtec\]: placebo controlled trial
Placebo
n=12 Participants
Placebo ODT appearing identical to the experimental formulation and administered every other day for 4 weeks/30 days Rimegepant 75 MG \[Nurtec\]: placebo controlled trial
Change in Rectal Sensation Pain Threshold
4.0 score on a scale
Interval -4.0 to 10.0
0.0 score on a scale
Interval -4.0 to 4.0

SECONDARY outcome

Timeframe: Baseline; Day 28

The change in rectal sensation ratings in response to 24 mmHg and 36 mmHg distensions measured using the 100-mm Visual analog scale (VAS). The scale ranges from (unnoticeable) to (unbearable). The VAS line will be 100 mm long with no intermediate delineations. Each end will be marked with "unnoticeable" on the left, and "unbearable" on the right. Participants will identify their sensation of pain, urgency and gas levels by indicating a point on the line between each end. That point will be measured from the "unnoticeable" end, and the number of millimeters will be reported as the pain, gas and urgency scores. Total scores range from 0 to 100 with higher scores indicating worsening sensation of pain, urgency and gas.

Outcome measures

Outcome measures
Measure
Rimegepant
n=12 Participants
* Rimegepant 75mg oral dissolving tablet (ODT) * Formulation and Dosing as FDA-approved for Migraine Prevention: 75 mg Every Other Day (EOD) for 4 weeks/30 days Rimegepant 75 MG \[Nurtec\]: placebo controlled trial
Placebo
n=12 Participants
Placebo ODT appearing identical to the experimental formulation and administered every other day for 4 weeks/30 days Rimegepant 75 MG \[Nurtec\]: placebo controlled trial
Change in Rectal Sensation Ratings in Response to 24 and 36 mmHg Distensions
Gas at 24 mmHg
-23.5 score on a scale
Interval -35.0 to -0.5
-7 score on a scale
Interval -21.0 to 14.0
Change in Rectal Sensation Ratings in Response to 24 and 36 mmHg Distensions
Urgency at 24 mmHg
-13.5 score on a scale
Interval -32.0 to -7.0
-6 score on a scale
Interval -14.0 to -0.5
Change in Rectal Sensation Ratings in Response to 24 and 36 mmHg Distensions
Pain at 24 mmHg
-11 score on a scale
Interval -29.0 to 1.0
4 score on a scale
Interval -2.0 to 10.0
Change in Rectal Sensation Ratings in Response to 24 and 36 mmHg Distensions
Gas at 36 mmHg
-1 score on a scale
Interval -26.0 to 6.0
-1 score on a scale
Interval -6.0 to 13.0
Change in Rectal Sensation Ratings in Response to 24 and 36 mmHg Distensions
Urgency at 36 mmHg
-12 score on a scale
Interval -27.0 to 2.0
0.5 score on a scale
Interval -5.0 to 8.0
Change in Rectal Sensation Ratings in Response to 24 and 36 mmHg Distensions
Pain at 36 mmHg
-12 score on a scale
Interval -20.0 to 9.0
3 score on a scale
Interval -1.0 to 8.0

SECONDARY outcome

Timeframe: Day 28

Percentage of solids moved from the stomach to the small intestine (gastric emptying) at 4 hours on Day 28.

Outcome measures

Outcome measures
Measure
Rimegepant
n=12 Participants
* Rimegepant 75mg oral dissolving tablet (ODT) * Formulation and Dosing as FDA-approved for Migraine Prevention: 75 mg Every Other Day (EOD) for 4 weeks/30 days Rimegepant 75 MG \[Nurtec\]: placebo controlled trial
Placebo
n=12 Participants
Placebo ODT appearing identical to the experimental formulation and administered every other day for 4 weeks/30 days Rimegepant 75 MG \[Nurtec\]: placebo controlled trial
Gastric Emptying of Solids
0.9 percentage of solids emptied
Interval 0.8 to 1.0
0.9 percentage of solids emptied
Interval 0.7 to 1.0

SECONDARY outcome

Timeframe: Baseline; Day 28

The scintigraphic method is used to measure colonic transit. An isotope is adsorbed on activated charcoal particles and delivered to the colon in a delayed release capsule. Anterior and posterior gamma images are taken at 4, 6, 8, 24, and 48 hours. The geometric center (GC) is the weighted average of counts in the different colonic regions. The scale ranges from 1 to 5; a high GC implies faster colonic transit, a GC of 1 implies all isotope is in the ascending colon, and a GC of 5 implies all isotope is in the stool.

Outcome measures

Outcome measures
Measure
Rimegepant
n=12 Participants
* Rimegepant 75mg oral dissolving tablet (ODT) * Formulation and Dosing as FDA-approved for Migraine Prevention: 75 mg Every Other Day (EOD) for 4 weeks/30 days Rimegepant 75 MG \[Nurtec\]: placebo controlled trial
Placebo
n=12 Participants
Placebo ODT appearing identical to the experimental formulation and administered every other day for 4 weeks/30 days Rimegepant 75 MG \[Nurtec\]: placebo controlled trial
Change in Colonic Transit at 24 Hours
-0.3 units on a scale
Interval -1.2 to 1.6
0.4 units on a scale
Interval -0.3 to 1.1

SECONDARY outcome

Timeframe: Day 28

The scintigraphic method is used to measure colonic transit. An isotope is adsorbed on activated charcoal particles and delivered to the colon in a delayed release capsule. Anterior and posterior gamma images are taken at 4, 6, 8, 24, and 48 hours. The geometric center (GC) is the weighted average of counts in the different colonic regions. The scale ranges from 1 to 5; a high GC implies faster colonic transit, a GC of 1 implies all isotope is in the ascending colon, and a GC of 5 implies all isotope is in the stool.

Outcome measures

Outcome measures
Measure
Rimegepant
n=12 Participants
* Rimegepant 75mg oral dissolving tablet (ODT) * Formulation and Dosing as FDA-approved for Migraine Prevention: 75 mg Every Other Day (EOD) for 4 weeks/30 days Rimegepant 75 MG \[Nurtec\]: placebo controlled trial
Placebo
n=12 Participants
Placebo ODT appearing identical to the experimental formulation and administered every other day for 4 weeks/30 days Rimegepant 75 MG \[Nurtec\]: placebo controlled trial
Colonic Transit at 48 Hours
4.7 units on a scale
Interval 2.7 to 5.0
4.3 units on a scale
Interval 2.8 to 4.9

SECONDARY outcome

Timeframe: Baseline; Day 28; Day 56

Irritable Bowel Syndrome Quality of Life (IBS-QOL) is a self-reported measure used to assess the impact of irritable bowel syndrome (IBS) on a participant's quality of life. The IBS-QOL consists of 34 items that cover eight distinct sub-domains, including emotional well-being, social functioning, dietary habits and intimate relationships. Each item is rated on a 5-point Likert scale, ranging from 1 (not at all) to 5 (a great deal). The raw scores are converted to a 0-100 scale where higher scores indicate a better quality of life.

Outcome measures

Outcome measures
Measure
Rimegepant
n=12 Participants
* Rimegepant 75mg oral dissolving tablet (ODT) * Formulation and Dosing as FDA-approved for Migraine Prevention: 75 mg Every Other Day (EOD) for 4 weeks/30 days Rimegepant 75 MG \[Nurtec\]: placebo controlled trial
Placebo
n=12 Participants
Placebo ODT appearing identical to the experimental formulation and administered every other day for 4 weeks/30 days Rimegepant 75 MG \[Nurtec\]: placebo controlled trial
Irritable Bowel Syndrome Quality of Life
Day 28
75 score on a scale
Interval 57.7 to 83.1
73.2 score on a scale
Interval 64.3 to 89.3
Irritable Bowel Syndrome Quality of Life
Baseline
61.4 score on a scale
Interval 46.3 to 70.6
74.3 score on a scale
Interval 53.7 to 84.9
Irritable Bowel Syndrome Quality of Life
Day 56
72.8 score on a scale
Interval 51.5 to 89.7
75 score on a scale
Interval 50.0 to 80.9

SECONDARY outcome

Timeframe: Day 1; Day 28

The number of participants who experienced an Adverse Event.

Outcome measures

Outcome measures
Measure
Rimegepant
n=12 Participants
* Rimegepant 75mg oral dissolving tablet (ODT) * Formulation and Dosing as FDA-approved for Migraine Prevention: 75 mg Every Other Day (EOD) for 4 weeks/30 days Rimegepant 75 MG \[Nurtec\]: placebo controlled trial
Placebo
n=12 Participants
Placebo ODT appearing identical to the experimental formulation and administered every other day for 4 weeks/30 days Rimegepant 75 MG \[Nurtec\]: placebo controlled trial
Number of Participants Who Experienced an Adverse Event
3 Participants
3 Participants

Adverse Events

Rimegepant

Serious events: 0 serious events
Other events: 3 other events
Deaths: 0 deaths

Placebo

Serious events: 0 serious events
Other events: 3 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure
Rimegepant
n=12 participants at risk
* Rimegepant 75mg oral dissolving tablet (ODT) * Formulation and Dosing as FDA-approved for Migraine Prevention: 75 mg Every Other Day (EOD) for 4 weeks/30 days Rimegepant 75 MG \[Nurtec\]: placebo controlled trial
Placebo
n=12 participants at risk
Placebo ODT appearing identical to the experimental formulation and administered every other day for 4 weeks/30 days Rimegepant 75 MG \[Nurtec\]: placebo controlled trial
Gastrointestinal disorders
Retching
0.00%
0/12 • Adverse events were collected from the date the participant received the first dose of medication through the washout period, approximately 56 days.
Adverse events were collected through non-leading questions, signs and symptoms detected during examination, laboratory evaluations, by observations of study personnel and by spontaneous reports from participants.
8.3%
1/12 • Adverse events were collected from the date the participant received the first dose of medication through the washout period, approximately 56 days.
Adverse events were collected through non-leading questions, signs and symptoms detected during examination, laboratory evaluations, by observations of study personnel and by spontaneous reports from participants.
Nervous system disorders
Migraine
0.00%
0/12 • Adverse events were collected from the date the participant received the first dose of medication through the washout period, approximately 56 days.
Adverse events were collected through non-leading questions, signs and symptoms detected during examination, laboratory evaluations, by observations of study personnel and by spontaneous reports from participants.
8.3%
1/12 • Adverse events were collected from the date the participant received the first dose of medication through the washout period, approximately 56 days.
Adverse events were collected through non-leading questions, signs and symptoms detected during examination, laboratory evaluations, by observations of study personnel and by spontaneous reports from participants.
Gastrointestinal disorders
Nausea
8.3%
1/12 • Adverse events were collected from the date the participant received the first dose of medication through the washout period, approximately 56 days.
Adverse events were collected through non-leading questions, signs and symptoms detected during examination, laboratory evaluations, by observations of study personnel and by spontaneous reports from participants.
0.00%
0/12 • Adverse events were collected from the date the participant received the first dose of medication through the washout period, approximately 56 days.
Adverse events were collected through non-leading questions, signs and symptoms detected during examination, laboratory evaluations, by observations of study personnel and by spontaneous reports from participants.
Gastrointestinal disorders
Vomiting
8.3%
1/12 • Adverse events were collected from the date the participant received the first dose of medication through the washout period, approximately 56 days.
Adverse events were collected through non-leading questions, signs and symptoms detected during examination, laboratory evaluations, by observations of study personnel and by spontaneous reports from participants.
8.3%
1/12 • Adverse events were collected from the date the participant received the first dose of medication through the washout period, approximately 56 days.
Adverse events were collected through non-leading questions, signs and symptoms detected during examination, laboratory evaluations, by observations of study personnel and by spontaneous reports from participants.
Infections and infestations
Rash
8.3%
1/12 • Adverse events were collected from the date the participant received the first dose of medication through the washout period, approximately 56 days.
Adverse events were collected through non-leading questions, signs and symptoms detected during examination, laboratory evaluations, by observations of study personnel and by spontaneous reports from participants.
0.00%
0/12 • Adverse events were collected from the date the participant received the first dose of medication through the washout period, approximately 56 days.
Adverse events were collected through non-leading questions, signs and symptoms detected during examination, laboratory evaluations, by observations of study personnel and by spontaneous reports from participants.
Nervous system disorders
Postural Orthostatic Tachycardia Syndrome
0.00%
0/12 • Adverse events were collected from the date the participant received the first dose of medication through the washout period, approximately 56 days.
Adverse events were collected through non-leading questions, signs and symptoms detected during examination, laboratory evaluations, by observations of study personnel and by spontaneous reports from participants.
8.3%
1/12 • Adverse events were collected from the date the participant received the first dose of medication through the washout period, approximately 56 days.
Adverse events were collected through non-leading questions, signs and symptoms detected during examination, laboratory evaluations, by observations of study personnel and by spontaneous reports from participants.
Gastrointestinal disorders
Change of bowel habit (reduced frequency)
16.7%
2/12 • Adverse events were collected from the date the participant received the first dose of medication through the washout period, approximately 56 days.
Adverse events were collected through non-leading questions, signs and symptoms detected during examination, laboratory evaluations, by observations of study personnel and by spontaneous reports from participants.
0.00%
0/12 • Adverse events were collected from the date the participant received the first dose of medication through the washout period, approximately 56 days.
Adverse events were collected through non-leading questions, signs and symptoms detected during examination, laboratory evaluations, by observations of study personnel and by spontaneous reports from participants.

Additional Information

Michael Camilleri, M.D., D.Sc.

Mayo Clinic

Phone: 507-266-2305

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place